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CObjectives: To quantify patient preferences whenmaking decisions as
to whether to accept latent tuberculosis infection (LTBI) preventive
treatment, using a discrete choice experiment (DCE). Methods: A DCE
urvey was developed and administered to LTBI patients. Each patient
as given 10 random choices along with two fixed choices to check
onsistency. Two hypothetical treatment options and one opt-out op-
ion were presented in each choice task. Latent class analysis was con-
ucted to estimate preferences for six key treatment attributes.
esults: Among the 214 respondents, 194 (90.7%) who provided valid
CE responses and complete sociodemographic information were in-
luded. Results consistently suggested that respondentswere averse to
igher risk of active tuberculosis and side effects and longer treatment.
three-latent-class model with five covariates was chosen. Forty-
even percent of the respondents were assigned to class 1, 32% to class
, and 21% to class 3. Although all six attributes were shown to signif-
cantly influence the respondents’ treatment decision, the risk of active O
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oi:10.1016/j.jval.2011.05.003uberculosis, chance of liver damage, and frequency of clinic visits
ere the most important ones. Significant preference heterogeneity
as observed in two attributes: frequency of clinic visits (P  0.01) and
hance of liver damage developing (P  0.01). Class 1 individuals were
ost likely to have children. Class 2 had the highest employment rate.
lass 3 respondents tended to choose the opt-out option on DCE tasks
ndweremore likely to be born outside Canada, havehigher education,
nd be unemployed. Conclusion: Respondents consistently preferred
reventive treatment with higher effectiveness, fewer side effects, and
horter length. Substantial preference heterogeneity existed among re-
pondents.
eywords: discrete choice experiment, latent class analysis, stated
reference, tuberculosis.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Tuberculosis (TB) continues to be a major public health threat
with one-third of world’s population infected [1,2]. Among im-
munocompetent individuals with latent TB infection (LTBI), in
approximately 10%, it will progress to active TB disease during
their lifetime. Because the majority of new active TB cases arise
in people with LTBI, preventing LTBI from developing into clin-
ical disease has both individual benefits and public health sig-
nificance [3,4]. Isoniazid (INH) has been long used for preventive
treatment and has well-established efficacy as demonstrated by
the results of multiple clinical trials [5–7]. The effectiveness of
preventive treatment in practice, however, has been limited by
low acceptance and poor adherence among patients [8–11]. In
ritish Columbia (BC), individuals with a diagnosis of LTBI are
ncouraged to see a physician to discuss preventive treatment,
hich consists of 9 months of INH managed through the TB
linics at the BC Centre for Disease Control (BCCDC). The treat-
* Address correspondence to: Carlo A. Marra, St. Paul’s Hospital, 6
E-mail: carlo.marra@ubc.ca.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.ment is publicly funded and is optional for the patients. In 2004,
in BC, 49.2% of people offered preventive treatment agreed
to initiate it; approximately 50% of these eventually completed
it [4].
A large body of research has intended to identify sociodemo-
graphic factors and other modifiable predictors associated with
poor adherence among patients receiving LTBI treatment [8–11].
owever, patients’ treatment decision -making has only been in-
estigated rarely [12]. Treatment decision making is a complex
ehavior, depending not only on the probability of risks and ben-
fits, but also on how patients perceive and value these parame-
ers and the associated uncertainties. As such, more effort needs
o be taken to understand the preferences influencing the accep-
ance of LTBI treatment. The primary objective of this studywas to
nderstand patients’ treatment decision-making processes
hrough quantifying their preferences for the preventive treat-
ent using a preference-elicitation technique: a discrete choice
xperiment (DCE).
1081 Burrard Street, Vancouver, BC V6Z 1Y6 Canada.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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ronmental economics, DCE methods have been recently adopted
in the health-care sector for a wide range of applications, e.g.,
understanding the decision-making process of patients and
health-care professionals, estimating willingness to pay, and pre-
dicting immunization uptake rates [13,14]. Based on Lancaster’s
economic theory of value, DCE assumes the commodity or product
of interest can be described by a few of its attributes or character-
istics, individuals derive utility from these underlying attributes
rather than the commodity per se, and individuals have prefer-
ence or utility for these attributes,which can be estimated through
the choices that they make [13,14].
To quantify respondents’ preferences, choices made in a DCE
urvey are analyzed under a randomutility theory framework [13].
Traditional logit or probit modeling approaches to analyzing
choice data are limited because they assume homogeneity of pref-
erences among respondents. Preferences for some treatment and
procedure attributes are expected to vary considerably across in-
dividuals, which may be related to observed factors (e.g., treat-
ment attributes and respondents’ sociodemographic features) and
unobservable characteristics (e.g. respondents’ attitude and per-
sonality) [15–17]. Ignoring the heterogeneity may bias the prefer-
ence estimates and lose the richness of information that could be
uncovered [16].
Mixed logit and latent class analysis are common approaches
to deal with preference heterogeneity and estimate the distribu-
tion of preferences for the attributes. In addition, latent classmod-
eling facilitates the grouping of respondents into a finite number
of latent classes with distinct preferences. The probability of class
membership and class-specific preference parameters can be es-
timated. Often used in marketing research, latent class analysis
could produce results leading to effective product targeting and
strategic positioning.
Methods
Development of the DCE survey
To identify treatment attributes for the DCE survey, semistruc-
tured individual interviews were conducted at the BCCDC TB
clinic. Twenty newly diagnosed LTBI patients were purposively
recruited to ensure that half of them had accepted the treatment
and half had declined it. After discussing with the physician, the
patients were invited to talk about their perceived motivating
factors and barriers of initiating the preventive treatment.
Based on interview results and expert opinions, six key attri-
butes with various levels (Table 1) were chosen: 1) length of
treatment; 2) frequency of clinic visits; 3) risk of the develop-
ment of active TB disease after treatment, which was used as an
indicator of the treatment effectiveness; 4) chance of liver dam-
age developing; 5) chance of skin rash developing; and 6) chance
of fatigue developing.
Sawtooth CBC/SSI Web V6.4.2 (Sawtooth Software, Inc., Se-
quim, WA) was used to generate 12 versions of DCE question-
naires. A fractional factorial experiment designwas appliedwhere
orthogonality, level balance, andminimal overlap were taken into
account [18]. Each version had 10 random choice sets plus two
identical fixed choices, and an example choice set is presented in
Figure 1. In each choice set, respondents were asked to compare
two hypothetical treatment options (A and B) and choose their
preferred one. An opt-out option of “neither” was also available
[19], which was explicitly defined as “lifetime risk of 10% of devel-
oping active TB disease without taking preventive treatment and
no risk of side effects.”
Located at question numbers 1 and 11 in the survey, the fixed
choices were included to check the validity and internal consis-
tency of the DCE design and responses [20,21]. In the fixed choiceset, one treatment option had clearly dominant or better attribute
levels, i.e., shorter but more effective and having fewer side ef-
fects. Respondents were expected to choose the better treatment
option if they understood the task and made rational decisions.
Responses to fixed choice sets were not included in data analysis.
In random choice tasks, on the other hand, treatment options
were carefully checked to limit the number of dominant scenarios
where no trade-off was needed. The survey was pilot tested
among 60 LTBI patients before final administration.
Subject recruitment and data collection
Subjects were recruited through BCCDC TB clinics if they 1) had a
diagnosis of LTBI, 2) were 19 years or older, and 3)were able to read
and understand English. Ethics approval was obtained from the
University of British Columbia Behavioural Research Ethics Board.
Data were collected using a questionnaire that included the DCE
survey and sociodemographic and TB-relevant information, such
as the reason for having a tuberculin skin test (TST) and bacille
Calmette-Guérin (BCG) vaccination status. A warm-up DCE choice
set was completed by each respondent. The subject could com-
plete the questionnaire at the clinic or complete it elsewhere and
bring it back on the next clinic visit.
Statistical analysis
Respondents were defined as consistent if they chose the better
treatment alternative or the neither option in the fixed consisten-
cy-check choice sets. Respondents who were inconsistent on both
fixed questions or had incomplete sociodemographic information
were excluded from data analysis. The sociodemographic charac-
teristics of included respondents were summarized using descrip-
tive statistics.
DCE choice data were analyzed using latent class analysis to
account for the preference heterogeneity among respondents.
All attribute variables were evaluated on a continuous scale
except for the variable frequency of clinic visits, which was
effect coded [22].
To determine the optimal number of latent classes, we esti-
mated a series of models with an increasing number of classes
from 2 to 10. Three information criteria, including log-likelihood,
Akaike Information Criteria, and Bayesian Information Criteria,
were used as a statistical guide to howmany classes to retain, i.e.,
the optimal number of classes was determined when an addi-
tional class would not significantly improve the model fit [15–17].
The significance of parameter estimates and the practical inter-
pretability of class membership were also considered. A manual
backward selection method was used to investigate sociodemo-
Table 1 – Attributes and levels to describe latent
tuberculosis infection preventive treatment.
Treatment attribute Levels Neither
option
Length of treatment 4, 6, 9, and 12 mo None
Frequency of clinic visit Every 2 mo, every 1 mo,
every 2 wk
None
Risk of active TB
developing after
treatment
0%, 1%, 2%, 4% 10%
Chance of liver damage
developing
0%, 1%, 3%, 5%, 10% 0%
Chance of skin rash
developing
0%, 5%, 10% 0%
Chance of fatigue
developing
0%, 5%, 10% 0%
TB, tuberculosis.graphic and other relevant variables for inclusion in the final la-
939V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 3 7 – 9 4 3tent class model as covariates, based on their influences on the
class membership.
Latent class analysis was performed using Latent GOLD ver-
sion 4.5 (Statistical Innovations Inc., Belmont, MA) and other
analyses were conducted using SAS version 9.1 (SAS Institute
Inc., Cary, NC).
Results
Respondents characteristics
Among the 214 respondents (Fig. 2), 10 (4.7%) were inconsistent on
both fixed choice sets and were excluded from data analysis; 4
(1.9%) chose the neither option throughout the survey irrespective
Fig. 1 – Example of a discretFig. 2 – Respondent recruiof the attribute levels given (i.e., nondemanders). Therefore, a total
of 204 (95.3%) were consistent on at least one fixed question. After
further excluding 10 respondents with incomplete sociodemo-
graphic information, 194 (90.7%) were included in choice data
analysis.
Table 2 summarizes the baseline characteristics of the 194 re-
spondents. Their average age was 38.0 years and 61.9% were fe-
male. Of the respondents, 85.6% were born outside Canada and
68.6% had Asian background. Among the 194 respondents, 80.9%
had college/university or higher education and 64.9% were cur-
rently employed. Of the respondents, 22.2% reported having other
health conditions, e.g., hypertension, arthritis, and diabetes. The
reasons for doing a screening TST varied: 19.6% were exposed to
an active TB patient, 16.5% did it for a medical reason or doctor’s
oice experiment choice set.e chtment and inclusion.
940 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 3 7 – 9 4 3recommendation, and 63.9% for school, employment, or immigra-
tion screening. Half of the respondents believed that they had
received BCG vaccination in the past.
Table 2 – Description of respondent baseline
characteristics.
Baseline characteristics N  194
Mean age, y (SD) 38.0 (11.8)
Female, n (%) 120 (61.9)
Born outside Canada, n (%) 166 (85.6)
Ethnic origin, n (%)
Asian 133 (68.6)
White 50 (25.8)
Others 11 (5.7)
Marital status, n (%)
Single 74 (38.1)
Married 102 (52.6)
Others 18 (9.3)
Have children, n (%) 104 (53.6)
Education, n (%)
High school or less 37 (19.1)
College/university 123 (63.4)
Postgraduate 34 (17.5)
Employed, n (%) 126 (64.9)
Annual household income*, n (%)
0–19,999 48 (24.7)
20,000–39,999 52 (26.8)
40,000–59,999 33 (17.0)
60,000–99,999 23 (11.9)
100,000 26 (13.4)
Prefer not to answer 12 (6.2)
Comorbidity, n (%) 43 (22.2)
On prescription medications, n (%) 69 (35.6)
On OTC medications, n (%) 32 (16.5)
BCG vaccination status, n (%)
Yes 100 (51.5)
No 37 (19.1)
Not sure 57 (29.4)
Reason for TST, n (%)
Contact of active TB case 38 (19.6)
Medical reason/Dr. referrals 32 (16.5)
School/employment/immigration 124 (63.9)
Know someone who had active TB, n (%) 51 (26.3)
* In Canadian dollars. BCG, bacille Calmette-Guérin; OTC, over the
counter; TB, tuberculosis; TST, tuberculin skin test.
Table 3 – Class-specific preference estimates.
Treatment attribute Class 1 mean (SE)
Length of treatment 0.08 (0.02)*
Frequency of clinic visit
No visit 2.29 (0.45)*
Every 2 mo 0.67 (0.18)*
Every 1 m 0.99 (0.17)*
Every 2 wk 0.63 (0.16)*
Risk of active TB developing 0.33 (0.04)*
Chance of liver damage developing 0.10 (0.03)*
Chance of skin rash developing 0.02 (0.02)
Chance of fatigue developing 0.05 (0.02)*
SE, standard error; TB, tuberculosis.
* Significant preference within the class (P  0.05).
† Significant difference across the three classes.Preference for LTBI treatment
Although the three model-fit statistical indicators did not show
clear convergence on an optimal number of latent classes, their
values were all leveling off at three- or four-class models and ad-
ditional increase in model fit with increasing number of classes
was marginal. Overall, including sociodemographic covariates
further improved the model fit. After further consideration of the
model simplicity and the interpretability of class membership, a
three-classmodelwith five sociodemographic covariateswas cho-
sen.
The class probabilities indicated that 47% of respondents were
assigned to class 1, 32% to class 2, and 21% to class 3. Table 3
presents the class-specific preference estimates, and the relative
importance of the six treatment attributes to each class is shown
in Figure 3.
As seen in Table 3, the preference estimates had the expected
direction. Respondents were consistently averse to a longer treat-
ment regimen andhigher risk of active TB, liver damage, skin rash,
and fatigue. Respondents were more concerned about serious
treatment side effects (i.e., liver damage) compared to relatively
mild ones (i.e., skin rash and fatigue). Among the six attributes,
chance of skin rash, chance of fatigue, and length of treatment
were of least importance to most respondents. These findings
were generally plausible and in line with our expectations, which
supported the theoretical validity (often assessed by determining
whether the estimated coefficients are of the anticipated signs and
consistent with a priori expectation) of our DCE methodology.
There was substantial heterogeneity in preferences across the
three classes, as indicated by differences in the sign, magnitude,
and significance of the class-specific parameter estimates (Table
3). TheWald statistic (Table 3) tests the statistical difference of the
preference estimates across the three classes and suggested that
significant preference heterogeneity among the three classes ex-
isted in two attributes, frequency of clinic visits (P  0.01) and
chance of liver damage developing (P  0.01).
Class 1 respondents had the lowest probability of choosing
the neither option in the DCE survey. They considered risk of
active TB developing and frequency of clinic visits most impor-
tant (Fig. 3) when choosing treatment, and they preferred a
clinic visit every 1 month over the other frequency options.
Monthly clinic visits are the current practice at BCCDC TB clin-
ics. Individuals in class 2 were most averse to the chance of liver
damage developing (Fig. 3). They preferred clinic visits every 2
months over other options. Class 3 respondents had the highest
probability of choosing the neither option in the DCE survey. In
class 3, respondents placed similarly important values on the
risk of active TB developing, chance of liver damage developing,
ss 2 mean (SE) Class 3 mean (SE) Wald P value
0.01 (0.03) 0.09 (0.04)* 0.17
0.01†
1.73 (0.44)* 1.80 (0.54)*
0.69 (0.19)* 0.60 (0.24)*
0.65 (0.20)* 0.55 (0.24)*
0.39 (0.16)* 0.65 (0.23)*
0.21 (0.06)* 0.31 (0.08)* 0.34
0.42 (0.05)* 0.23 (0.04)* 0.01†
0.05 (0.02)* 0.05 (0.03) 0.53
0.03 (0.02) 0.03 (0.03) 0.69Cla
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941V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 3 7 – 9 4 3and frequency of clinic visits (Fig. 3) in treatment choices. They
referred no clinic visits.
We foundfive sociodemographic factors thatwere significantly
ssociated with the membership of preference classes, including
rigin of birth, having children, education level, employment sta-
us, and over-the-counter (OTC) medications. Table 4 describes
he different sociodemographic profiles of the three classes. Indi-
iduals in class 1 were most likely to have children among the
hree classes (62.6% vs. 43.5% and 48.6%). Those in class 2 had the
ighest employment rate among respondents (78.3% vs. 66.1% and
1.8%). Class 3 respondents were most likely to be born outside
anada (97.7% vs. 80.0% and 85.9%), have higher education (college
r higher: 95.0% vs. 78.5% and 74.8%), be unemployed (58.2% vs.
3.9% and 21.7%), and take OTC medications (27.4% vs. 14.7% and
2.1%).
Discussion
To our knowledge, this is the first study to quantify patient pref-
erences for LTBI treatment using a DCE technique with a robust
latent class analysis approach. Methodologically, our study illus-
trates how the DCE technique could be an internally consistent
and valid tool to understand patient preferences for health prod-
ucts and interventions. Theuse of latent class analysis allowsus to
identify and categorize the preference heterogeneity among re-
spondents. Incorporating sociodemographic variables could pro-
vide intuitive and informative information that could potentially
help inform health-care practice.
As expected, respondents were consistently in favor of shorter
length of treatment, lower risk of side effects, and higher effective-
ness. Among the three side effects, respondents were much more
concerned about the rare but serious one (i.e., liver damage) than
themore commonmild/moderate ones (i.e., skin rash and fatigue).
These findings were generally plausible and congruent with our
hypotheses, which greatly supported the theoretical validity of
our DCE survey.
Three factors, the risk of active TB developing, the chance of
liver damage developing, and the frequency of clinic visits,were
he most important determinants on treatment decision mak-
ng for the majority of respondents. Although previous studies
ound that the length of regimen was a critical predictor of LTBI
Fig. 3 – Relative imreatment adherence and completion among patients receiving ereatment [10–12], our results revealed that treatment benefits
nd potential side effects were more important than its length
hen patients decided whether to initiate the treatment. As we
bserved in practice, a fair proportion of patients agree to start
he 9-month INH regimen but stop it after awhile, even without
xperiencing side effects. This suggests that initial decision
aking and treatment adherence are different behaviors and
eed to be examined and targeted differently.
Our results revealed that patients’ preferences varied signifi-
antly when making decisions regarding LTBI preventive treat-
ent. A three-latent-classmodel appeared to best fit our data. We
ssociated the class membership with five measurable sociode-
ographic factors. Overall, the class-specific preferences made
ense with the characteristics of each class.
Class 1 individualsmay be representative of people who tend
o adhere to the preventive treatment and the current practice
t TB clinics (i.e., monthly clinic visits). They seemed to care a
ot about getting rid of the infection and not be discouraged by
he risk of a serious side effect (i.e., liver damage). They were
ost likely to have children. As we learned from patient inter-
iews, an important motivating factor for many people to initi-
te the preventive treatment was to protect their family, especially
hildren. Class 1 was the largest group, with approximately 47% of
he sample, followed by class 2with 32%and class 3with 21%. In our
ample of LTBI patients, however, people who refused or tended
o refuse the preventive treatment might be underrepresented
or two reasons. First, among people diagnosed with LTBI, a
arge proportion of them did not come to the TB clinic to discuss
he preventive treatment. It was likely that these individuals
ad already made up their minds to refuse the treatment and
id not bother to discuss it with a TB physician. Second, we
bserved that patients who eventually refused the treatment
ere less likely to agree to participate in our study. We were
nable to investigate the differences between patients who
greed to participate and those who refused to participate due
o ethics constraints.
Class 2 respondents were concerned most about the potential
isk of liver damage. Those in class 2 had the highest employment
ate and preferred less frequent clinic visits. One possible motiva-
or for them to initiate the preventive treatment might be the ob-
igation or pressure from school or work, mostly in health care or
ance of attributes.portarly education. Class 3 respondents had the highest probability of
942 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 3 7 – 9 4 3choosing the neither option in the DCE and might be likely to
refuse the preventive treatment in reality. They were more likely
to be born outside Canada, unemployed, highly educated, or tak-
ing OTCmedications. Most of our respondents were born in Asian
countries where BCG vaccination is a routine practice. The fact
that the TST, the LTBI diagnostic test, is highly confounded by BCG
may play a role in the high rate of those refusing the preventive
treatment among the foreign born. For unemployed individuals,
current living needs or being busy with school possibly left them
little time or energy to consider preventing a disease that might
only happen in the future. It is interesting that higher education
was found to be associated with a tendency to refuse preventive
treatment. It is possible that people with higher education tend to
choose a healthy lifestyle and believe they havemore control over
their own health. They would be less concerned about an infec-
tious disease such as TB, which is often associated with lower
socioeconomic status.
There has been research attempting to identify factors that may
affect or predict individual judgment of their preferences, e.g., so-
ciodemographic features, individuals’ risk attitudes (risk seeking vs.
riskaverse), and individuals’ perceivedcontrol over their ownhealth.
In our study, we found a number of patients’ sociodemographic fac-
tors were significantly associated with the preference heterogeneity
that we observed. Previous studies yielded few results on this topic.
One study showed that osteoarthritis patients’ preferences varied
widely in therapeutic decisions, but their clinical, sociodemographic,
and psychological characteristics were not found to explain the het-
erogeneity [23]. This study, however, applied a probabilistic thresh-
old technique, different from our DCEmethodology.
Our results underline the importance and value of account-
ing for preference heterogeneity when analyzing choice data.
Model-fit statistics suggested that latent class model fit our data
better than traditional conditional logit model, and including
sociodemographic covariates further improved the model fit.
Latent class analysis provides richer information that would not
be observed with more traditional conditional logit approaches.
The use of latent class analysis allows us to categorize respon-
dents’ preferences and helps us better understand how respon-
dents perceive the risks and benefits differently and weigh
treatment attributes differently in decision making. This infor-
mation could possibly assist health-care professionals in effec-
tive communication with patients when advocating preventive
treatment, which would lead to improved treatment accep-
tance.
Methodological concerns over DCE’s experimental design,
sample size and selection, and choice data collection and analysis
have beenwidely discussed. Although no definitive answers to the
optimal sample size, a few issues are recommended to consider,
e.g., the number of attributes, complexity of choice tasks, statisti-
cal approach used to analyze choice data, degree of desired preci-
sion, and budget [14,24]. In addition, an often-used rule in regres-
sion analysis suggests that a minimum of 10 dependent variable
observations is required for each independent variable. Our sam-
ple size of 194 was enough to fit a latent class model with six
attribute variables and five covariates.
We ensured the validity of the DCE design through carefully
choosing treatment attributes by patient interviews and expert
opinions and piloting the survey before final administration. To
further improve the validity and quality of DCE choice data, a
warm-up choice task was practiced with the researcher by each
respondent before completing the survey. We also incorporated
two fixed consistency-check questions in each version of the sur-
vey. Only 4.7% of the respondents failed both questions. These
respondents were likely to not fully understand the DCE tasks and
might not have made meaningful choices. Therefore, their re-
sponses were excluded from analysis to ensure the quality of our
choice data. Further considering the fact that most respondentsspoke English as their second language, our DCE survey was well
understood and accepted. Finally, our results were clinically and
practically plausible, which supported the theoretical validity of
our DCE methodology.
The most expressed concern regarding the DCE technique has
been that stated preference may not reflect true preference and
not be able to predict individuals’ real-life behavior in an actual
market situation (i.e., revealed preference) [25–27]. In a well-con-
trolled experimental context, DCE choice tasks may simplify real-
life decision making, and respondents may be not willing or not
able to express their true preferences. One effective approach to
addressing this concern would be to compare the stated choices
from the DCE surveywith actual decision-making behavior, which
would provide the strongest evidence to support the validity of the
DCE technique. This is an important avenue for future research in
applying DCE techniques in health care.
Conclusions
The DCE technique offers a promising tool to understand patients’
decision-making processes regarding health products and ser-
vices and to potentially informhealth-care practice. To extend the
usefulness of DCE in informing health-care practice, future effort
should be directed to validating this technique. This study also
highlights the use of latent class analysis in preference studies as
an area of potentially novel research in health economics that
requires further empirical applications.
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